Effects of intestinal flora on the occurrence and development of type 2 diabetes mellitus and diabetic foot
WANG Jialin1 WANG Yuqing1 HUANG Xiaoting1 ZHOU Mingmei2 ZHAO Cheng3▲#br#
1.Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2.Institute for Interdisciplinary Medicine Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
3.Department of Vascular Diseases, Shanghai Traditional Chinese Medicine Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
Abstract：Type 2 diabetes mellitus and its complications are a common health problem endangering health today, and its incidence is increasing year by year. Cardiovascular, renal, and peripheral nerve complications related to type 2 diabetes mellitus accelerate the risk of disability or death in patients. Some studies have shown that intestinal flora disorders can increase the incidence of type 2 diabetes mellitus and diabetic foot by affecting blood lipids, blood pressure, and glucolipid metabolism, and thus affect the development and prognosis of these diseases. Intestinal flora research is a new entry point for the prevention and treatment of a series diseases including type 2 diabetes and diabetic foot. In this paper, the recent studies on the effects of intestinal flora on the occurrence and development of type 2 diabetes mellitus and type 2 diabetic foot.
王嘉霖1 王玉晴1 黄晓停1 周明眉2 赵诚3▲. 肠道菌群对2型糖尿病及糖尿病足发生发展的影响[J]. 中国医药导报, 2022, 19(36): 54-57,65.
WANG Jialin1 WANG Yuqing1 HUANG Xiaoting1 ZHOU Mingmei2 ZHAO Cheng3▲. Effects of intestinal flora on the occurrence and development of type 2 diabetes mellitus and diabetic foot. 中国医药导报, 2022, 19(36): 54-57,65.
[1] Fan Y，Pedersen O. Gut microbiota in human metabolic health and disease [J]. Nat Rev Microbiol，2021，19（1）：55-71.
[2] Liu C，Yang SY，Wang L，et al. The gut microbiome：implications for neurogenesis and neurological diseases [J]. Neural Regen Res，2022，17（1）：53-58.
[3] 陆淋丽，鞠海兵.微生态制品调节肥胖肠道微生物的研究进展[J].中国当代医药，2021，28（26）：51-55.
[4] 严人，江慧勇，李兰娟.人体微生态与健康和疾病[J].微生物学报，2017，57（6）：793-805.
[5] 张丹.2型糖尿病与肠道菌群的关系[J].世界最新医学信息文摘，2017，17（81）：252-253.
[6] Rinninella E，Raoul P，Cintoni M，et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age，Environment，Diet，and Diseases [J]. Microorganisms，2019，7（1）：14.
[7] Wang JW，Pan YB，Cao YQ，et al. Loganin alleviates LPS- activated intestinal epithelial inflammation by regulating TLR4/NF-κB and JAK/STAT3 signaling pathways [J]. Kaohsiung J Med Sci，2020，36（4）：257-264.
[8] Dong N，Li X，Xue C，et al. Astragalus polysaccharides alleviates LPS-induced inflammation via the NF-κB/MAPK signaling pathway [J]. J Cell Physiol，2020，235（7/8）：5525- 5540.
[9] Pitocco D，Spanu T，Di Leo M，et al. Diabetic foot infections：a comprehensive overview[J]. Eur Rev Med Pharmacol Sci，2019，23（2 Suppl）：26-37.
[10] Komaroff AL. The microbiome and risk for obesity and diabetes [J]. JAMA，2017，317（3）：355-356.
[11] Hu L，Zhu S，Peng X，et al. High Salt Elicits Brain Inflammation and Cognitive Dysfunction，Accompanied by Alternations in the Gut Microbiota and Decreased SCFA Production [J]. J Alzheimers Dis，2020，77（2）：629-640.
[12] Yang G，Wei J，Liu P，et al. Role of the gut microbiota in type 2 diabetes and related diseases [J]. Metabolism，2021，117：154712.
[13] He Z，Xue Z，Lin S，et al. Gut microbiota profile in patients with type 1 diabetes based on 16S rRNA gene sequencing：a systematic review [J]. Dis Markers，2020：3936247.
[14] Kací■ová M，Zme?觢kalová A，Ko■ínková L，et al. Inflammation：major denominator of obesity，Type 2 diabetes and Alzheimer's disease-like pathology? [J]. Clin Sc（Lond），2020，134（5）：547-570.
[15] Radwan S，Gilfillan D，Eklund B，et al. A comparative study of the gut microbiome in Egyptian patients with Type Ⅰ and Type Ⅱ diabetes [J]. PLoS One，2020，15（9）：e238764.
[16] J Belizario，J Faintuch，Garay-Malpartida M，et al. Gut microbiome dysbiosis and immunometabolism：new frontiers for treatment of metabolic diseases [J]. Mediators Inflamm，2018：2037838.
[17] Ducarmon QR，Zwittink RD，Hornung B，et al. Gut microbiota and colonization resistance against bacterial enteric infection [J]. Microbiol Mol Biol Rev，2019，83（3）：e00007- 19.
[18] Zhao L，Zhang F，Ding X，et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes [J]. Science，2018，359（6380）：1151-1156.
[19] Le Bourgot C，Apper E，Blat S，et al. Fructo oligosaccharides and glucose homeostasis：a systematic review and meta-analysis in animal models [J]. Nutr Metab（Lond），2018，15：9.
[20] Noor S，Zubair M，Ahmad J. Diabetic foot ulcer——a review on pathophysiology，classification and microbial etiology [J]. Diabetes Metab Syndr，2015，9（3）：192-199.
[21] Schoeler M，Caesar R. Dietary lipids，gut microbiota and lipid metabolism [J]. Rev Endocr Metab Disord，2019，20（4）：461-472.
[22] Koutnikova H，Genser B，Monteiro Sepulveda M. et al. Impact of bacterial probiotics on obesity，diabetes and non alcoholic fatty liver disease related variables：a systematic review and meta analysis of randomised controlled trials [J]. 2019，9（3）：e017995.
[23] Pieczynska MD，Yang Y，Petrykowski S，et al. Gut Microbiota and Its Metabolites in Atherosclerosis Development [J]. Molecules，2020，25（3）：594.
[24] Ramírez-Pérez O，Cruz-Ramón V，Chinchilla-López P，et al. The Role of the Gut Microbiota in Bile Acid Metabolism [J]. Ann Hepatol，2017，16（Suppl.1：s3-105.）：s15-s20.
[25] Pirri C，Fede C，Pirri N，et al. Diabetic Foot：The Role of Fasciae，a Narrative Review [J]. Biology（Basel），2021，10（8）：759.
[26] Akash M，Rehman K，Fiayyaz F，et al. Diabetes-associated infections：development of antimicrobial resistance and possible treatment strategies [J]. Arch Microbiol，2020（5）：953-965.
[27] Munoz LD，Sweeney MJ，Jameson JM. Skin Resident γδ T Cell Function and Regulation in Wound Repair [J]. Int J Mol Sci，2020，21（23）：9286.
[28] Tanase DM，Gosav EM，Neculae E，et al. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes（T2DM）[J]. Nutrients，2020， 12（12）：3719.
[29] Tembhre MK，Chawla MK，Berthiaume F，et al. Relationship Between Probiotics and Gut-Skin Axis in Skin Wound Healing：A Recent Update [J]. Probiotic Res Ther，2021：173-196.
[30] Prompers L，Huijberts M，Apelqvist J，et al. High prevalence of ischaemia，infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study [J]. Diabetologia，2007，50（1）：18-25.
[31] Glaudemans AW， U?觭kay I，Lipsky BA，Challenges in diagnosing infection in the diabetic foot [J]. Diabet Med，2015， 32（6）：748-759
[32] Sekhar MS，Unnikrishnan MK，Vijayanarayana K，et al. Topical application/formulation of probiotics：Will it be a novel treatment approach for diabetic foot ulcer? [J]. Med Hypotheses，2014，82（1）：86-88.
[33] Hill C，Guarner F，Reid G，et al. Expert consensus document：The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic [J]. Nat Rev Gastroenterol Hepatol，2014，11（8）：506-514.
[34] Ohseni S，Bayani M，Bahmani F，et al. The beneficial effects of probiotic administration on wound healing and metabolic status in patients with diabetic foot ulcer：A randomized，double-blind，placebo-controlled trial [J]. Diabetes Metab Res Rev，2018，34（3）：e2970.
[35] Oelschlaeger TA. Mechanisms of probiotic actions-A review [J]. Int J Med Microbiol，2010，300（1）：57-62.
[36] Salga?觭o MK，Oliveira L，Costa GN，et al. Relationship between gut microbiota，probiotics，and type 2 diabetes mellitus [J]. Appl Microbiol Biotechnol，2019，103（23/24）：9229-9238.
京公网安备 11010502046598号